Across TCGA pan-cancer cohorts, HCP5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HCP5 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher HCP5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HCP5 expression acts as an unfavorable survival marker.

BLCA, KIRP, and SKCM are the cancer types where HCP5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.121	0.615	.002	18	view →
KIRP	DFS	Median	All	0.178	0.829	<.001	10	view →
SKCM	DFS	Median	All	0.046	0.757	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HCP5 tumor-vs-normal RNA expression · all HCP5 data types